Nicolas Mounier
About
In The Last Decade
Nicolas Mounier
201 papers receiving 8.1k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Pathology and Forensic Medicine 6.1k
- Oncology 4.5k
- Genetics 2.0k
- Neurology 1.7k
- Immunology 1.3k
Countries citing papers authored by Nicolas Mounier
This map shows the geographic impact of Nicolas Mounier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Mounier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Mounier more than expected).
Fields of papers citing papers by Nicolas Mounier
This network shows the impact of papers produced by Nicolas Mounier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Mounier. The network helps show where Nicolas Mounier may publish in the future.
Co-authorship network of co-authors of Nicolas Mounier
This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Mounier. A scholar is included among the top collaborators of Nicolas Mounier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Mounier. Nicolas Mounier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 15 | |
| 2 | 5 | |
| 3 | 14 | |
| 4 | Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era breakdown → | 1117 |
| 5 | 84 | |
| 6 | 90yttrium Ibritumomab Tiuxetan (zevalin) Combined With Beam (z-beam) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed Or Refractory Follicular Lymphoma. a Gela Phase Ii Prospective Study | 1 |
| 7 | 16 | |
| 8 | 239 | |
| 9 | 97 | |
| 10 | 46 | |
| 11 | 161 | |
| 12 | 5 | |
| 13 | 162 | |
| 14 | Prognostic factors for aggressive lymphoma patients treated with front-line autotransplantation after complete remission: A cohort study on 330 patients | 1 |
| 15 | Final results of the efficacy and safety of rasburicase (recombinant urate oxydase) for the prevention and treatment of hyperuricemia in patients with aggressive lymphoma (GRAAL 1 study). | 4 |
| 16 | Radiotherapy is unnecessary in elderly patients with localized agressive non Hodgkin's lymphoma: results of the LNH 93-4 study | 14 |
| 17 | [Monoclonal antibodies in the treatment of lymphoma]. | 0 |
| 18 | 30 | |
| 19 | Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study. | 5 |
| 20 | Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients. | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.